Evelo Biosciences, Inc.
EVLO · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $681 | $18,131 | $20,073 | $176,841 |
| - Cash | $17,262 | $7,622 | $27,472 | $47,940 |
| + Debt | $33,948 | $50,481 | $50,696 | $51,138 |
| Enterprise Value | $17,367 | $60,990 | $43,297 | $180,039 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$793 | -$1,616 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$11,050 | -$19,077 | -$23,640 | -$20,637 |
| % Margin | – | – | – | – |
| Net Income | -$12,364 | -$21,103 | -$25,341 | -$23,541 |
| % Margin | – | – | – | – |
| EPS Diluted | -71.12 | -3.78 | -4.57 | -4.29 |
| % Growth | -1,781.5% | 17.3% | -6.5% | – |
| Operating Cash Flow | -$10,408 | -$19,827 | -$20,276 | -$23,190 |
| Capital Expenditures | -$47 | $0 | -$12 | -$228 |
| Free Cash Flow | -$10,455 | -$19,827 | -$20,288 | -$23,418 |